178 related articles for article (PubMed ID: 6821701)
21. The influence of salicylate on platelets and whole blood adenine nucleotides.
Davies DT; Hughes A; Tonks RS
Br J Pharmacol; 1969 Jul; 36(3):437-47. PubMed ID: 5789804
[TBL] [Abstract][Full Text] [Related]
22. Platelet adhesion and mural platelet thrombus formation on aortic subendothelium of rats, rabbits, and guinea pigs correlate negatively with the vascular PGI2 production.
Tschopp TB; Baumgartner HR
J Lab Clin Med; 1981 Sep; 98(3):402-11. PubMed ID: 7021720
[TBL] [Abstract][Full Text] [Related]
23. Coagulation, fibrinolytic and platelet function in patients on long-term therapy with aspirin 300 mg or 1,200 mg daily compared with placebo.
Hampton KK; Cerletti C; Loizou LA; Bucchi F; Donati MB; Davies JA; de Gaetano G; Prentice CR
Thromb Haemost; 1990 Aug; 64(1):17-20. PubMed ID: 2073296
[TBL] [Abstract][Full Text] [Related]
24. Increased blood fibrinolytic activity after aspirin ingestion.
Moroz LA
N Engl J Med; 1977 Mar; 296(10):525-9. PubMed ID: 836536
[TBL] [Abstract][Full Text] [Related]
25. Effects of aspirin and prostaglandin E1 on in vitro thrombolysis with urokinase. Evidence for a possible role of inhibiting platelet activity in thrombolysis.
Terres W; Beythien C; Kupper W; Bleifeld W
Circulation; 1989 Jun; 79(6):1309-14. PubMed ID: 2720929
[TBL] [Abstract][Full Text] [Related]
26. Sex related differences in platelet function: the effect of aspirin.
Kelton JG; Carter CJ; Santos A; Hirsh J
Blood; 1982 Mar; 59(3):625-7. PubMed ID: 7059670
[TBL] [Abstract][Full Text] [Related]
27. Antagonism of the GPIIb/IIIa receptor with the nonpeptidic molecule BIBU52: inhibition of platelet aggregation in vitro and antithrombotic efficacy in vivo.
Guth BD; Seewaldt-Becker E; Himmelsbach F; Weisenberger H; Müller TH
J Cardiovasc Pharmacol; 1997 Aug; 30(2):261-72. PubMed ID: 9269956
[TBL] [Abstract][Full Text] [Related]
28. Reversal of shortened platelet survival in rats by the antifibrinolytic agent, epsilon aminocaproic acid.
Winocour PD; Kinlough-Rathbone RL; Richardson M; Mustard JF
J Clin Invest; 1983 Jan; 71(1):159-64. PubMed ID: 6848557
[TBL] [Abstract][Full Text] [Related]
29. Pharmacology of platelet inhibition in humans: implications of the salicylate-aspirin interaction.
de Gaetano G; Cerletti C; Dejana E; Latini R
Circulation; 1985 Dec; 72(6):1185-93. PubMed ID: 2998640
[TBL] [Abstract][Full Text] [Related]
30. The effect of acetylsalicyclic acid on platelet function.
Evans G; Packham MA; Nishizawa EE; Mustard JF; Murphy EA
J Exp Med; 1968 Nov; 128(5):877-94. PubMed ID: 4176225
[TBL] [Abstract][Full Text] [Related]
31. Effect of SR121566A, a potent GP IIb-IIIa antagonist on platelet-mediated thrombin generation in vitro and in vivo.
Herault JP; Peyrou V; Savi P; Bernat A; Herbert JM
Thromb Haemost; 1998 Feb; 79(2):383-8. PubMed ID: 9493595
[TBL] [Abstract][Full Text] [Related]
32. Action of gold sodium thiomalate on experimental thrombosis in vivo.
Kean WF; Lock CJ; Somers D; Rischke J; Nablo L; Kassam YB; Hogan MG; Buchanan WW; Howard-Lock HE
J Pharm Sci; 1991 Feb; 80(2):113-8. PubMed ID: 1904936
[TBL] [Abstract][Full Text] [Related]
33. Glycoprotein Ibalpha inhibition and ADP receptor antagonists, but not aspirin, reduce platelet thrombus formation in flowing blood exposed to atherosclerotic plaques.
Penz SM; Reininger AJ; Toth O; Deckmyn H; Brandl R; Siess W
Thromb Haemost; 2007 Mar; 97(3):435-43. PubMed ID: 17334511
[TBL] [Abstract][Full Text] [Related]
34. Low dose aspirin does not prevent fibrinolytic response to venous occlusion.
de Gaetano G; Carriero MR; Cerletti C; Mussoni L
Biochem Pharmacol; 1986 Sep; 35(18):3147-50. PubMed ID: 3755907
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of the antithrombotic activity of Zhi-Xiong Capsules, a Traditional Chinese Medicinal formula, via the pathway of anti-coagulation, anti-platelet activation and anti-fibrinolysis.
Zhou J; Song Z; Han M; Yu B; Lv G; Han N; Liu Z; Yin J
Biomed Pharmacother; 2018 Jan; 97():1622-1631. PubMed ID: 29793324
[TBL] [Abstract][Full Text] [Related]
36. Platelet deposition induced by severely damaged vessel wall is inhibited by a boroarginine synthetic peptide with antithrombin activity.
Badimon JJ; Weng D; Chesebro JH; Fuster V; Badimon L
Thromb Haemost; 1994 Apr; 71(4):511-6. PubMed ID: 8052972
[TBL] [Abstract][Full Text] [Related]
37. Oral thrombin inhibitor aggravates platelet adhesion and aggregation during arterial thrombosis.
Petzold T; Thienel M; Konrad I; Schubert I; Regenauer R; Hoppe B; Lorenz M; Eckart A; Chandraratne S; Lennerz C; Kolb C; Braun D; Jamasbi J; Brandl R; Braun S; Siess W; Schulz C; Massberg S
Sci Transl Med; 2016 Nov; 8(367):367ra168. PubMed ID: 27903864
[TBL] [Abstract][Full Text] [Related]
38. The role of platelet hyperfunction in thrombus formation in hyperlipidemia.
Suehiro A; Kakishita E; Nagai K
Thromb Res; 1982 Feb; 25(4):331-9. PubMed ID: 6803387
[TBL] [Abstract][Full Text] [Related]
39. The effect of aspirin on the size of the hemostatic plug.
Kelton JG; Carter CJ
Thromb Res; 1983 Nov; 32(3):267-73. PubMed ID: 6362058
[TBL] [Abstract][Full Text] [Related]
40. Tyrosine Kinase Inhibitor Sunitinib Delays Platelet-Induced Coagulation: Additive Effects of Aspirin.
Tullemans BME; Fernández DI; Veninga A; Baaten CCFMJ; Peters LJF; Aarts MJB; Eble JA; Campello E; Spiezia L; Simioni P; van der Vorst EPC; van der Meijden PEJ; Heemskerk JWM; Kuijpers MJE
Thromb Haemost; 2022 Jan; 122(1):92-104. PubMed ID: 34130349
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
